Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL-4030
- Development stage
- Unknown
- Lead developer
- Biokin Pharmaceutical
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BL-4030 is an investigational, first-in-class trispecific antibody developed by Sichuan Baili Pharmaceutical (Baili-Tianyu) and its subsidiary SystImmune. It is designed to simultaneously target three key pathways involved in tumor growth and angiogenesis: the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 3 (HER3), and vascular endothelial growth factor A (VEGF-A). By binding to these three targets, BL-4030 aims to provide a synergistic therapeutic effect, inhibiting tumor cell proliferation and survival while also suppressing the formation of new blood vessels that support tumor growth. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, particularly those that have become resistant to standard therapies.
02
Targets
EGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on BL-4030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL-4030.